Damage to myelin, the protective sheath surrounding nerve fibers, impairs the brain's ability to transmit signals efficiently ...

Guillain-Barré Syndrome (GBS) is a rare autoimmune disorder where the immune system attacks peripheral nerves, causing ...

LPXTI-641 is under clinical development by Lapix Therapeutics and currently in Phase I for Demyelinating Diseases. According to GlobalData, Phase I drugs for Demyelinating Diseases have a 73% phase ...

Binge eating disorder can seriously affect a person’s physical and mental health. Cognitive behavioral therapy (CBT) is the most effective treatment. Healthcare professionals can prescribe it ...

Riliprubart is under clinical development by Sanofi and currently in Phase III for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According to GlobalData, Phase III drugs for Chronic ...

Inflammatory bowel disease (IBD) is a group of intestinal disorders that cause prolonged inflammation of the digestive tract. It can include ulcerative colitis (UC) or Crohn’s disease.

An organic disease is one in which there is a measurable change to tissues, organs, or body systems. A functional disease is one in which there are abnormal symptoms or changes in function but with no ...

MS is a chronic disease caused by demyelination, often associated with a wide range of neurological symptoms, which despite the ability of existing drugs to control the inflammatory component of ...

The current human tissue-based study provides convincing evidence correlating hippocampal expressions of RNA guanine-rich G-quadruplexes with aging and with Alzheimer's Disease presence and severity.

A fully funded Gavi is a vital pillar of global health, safeguarding immunisation coverage, reducing health inequities, and preventing disease incidence and child mortality, particularly in low-income ...

“This relatively recent but increasingly significant idea in the field has the potential to address critical questions on detailed mechanisms of neuroinflammatory and demyelinating diseases, such as ...